Kornimate/medical-research-clean huggingface dataset:
role of individualized peep vs fixed peep in mechanical ventilation during laparoscopic surgeries

Conditions: Laparoscopic Surgery; Pneumoperitoneum; Positive End Expiratory Pressure (PEEP)

Summary: to compare the effects of individualized positive end-expiratory pressure with recruitment maneuver on respiratory parameters and oxygenation in mechanical ventilation during laparoscopic surgeries with the fixed positive end-expiratory pressure and conventional mechanical ventilation without positive end-expiratory pressure.

thus study will compare the effects different methods of positive end-expiratory pressure administration in mechanical ventilation on respiratory parameters and oxygenation of the patients undergoing laparoscopic surgeries. there will be three groups of patients which will be as follows: individualized positive end-expiratory pressure with recruitment maneuver group, fixed positive end-expiratory pressure group and conventional mechanical ventilation. respiratory parameters; dynamic compliance, driving pressure and ratio of partial pressure of oxygen to fractional inspiration of oxygen will be measured. mechanical ventilation respiratory parameters i .e. peak pressure, plateu pressure , dynamic compliance and driving pressure will be measured from ventilator machine. p/f ratio( ratio of partial pressure of oxygen to inspiratory fraction of oxygen) will be measured by taking blood samples for arterial blood gas analysis.

Eligibility criteria:
inclusion criteria: * 1. age limit : 25 years to 65 years 2. patients undergoing laparoscopic suregeries 3. asa 1-3 exclusion criteria: * 1. hemodynamic instability 2. bronchospam 3. patients having copd 4. history of pulmonary bulla 5. patients having history of pneumothora

Keywords: mechanical ventilation lung compliance positive end-expiratory pressure respiratory mechanics oxygenation index driving pressure
pompe lactation sub-registry

Conditions: Glycogen Storage Disease; Pompe Disease

Summary: the objective is to determine if alglucosidase alfa is present in breast milk from mothers with pompe disease being treated with alglucosidase alfa and to measure breast milk production and composition in women with pompe disease who receive alglucosidase alfa.


Eligibility criteria:
inclusion criteria: * must be enrolled in pompe registry (nct00231400) * must be pregnant and intend to breast-feed or be currently lactating and receive at least one infusion of alglucosidase alfa while lactating * provide a signed patient information and authorization form to participate in the sub-registry prior to any sub-registry-related assessments are performed * agree to adhere to the sub-registry guidelines for antibody testing and recommended schedule of assessments. exclusion criteria: * patients will be excluded from this sub-registry if they have received an investigational drug (excluding alglucosidase alfa in regions where alglucosidase alfa is not commercially available) within 30 days prior to visit 1 breast milk collection

Keywords: glycogen storage disease gsd-ii pompe disease pompe disease (late-onset) acid maltase deficiency disease glycogenosis ii
the relationship of serum uric acid with severity of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: osteoarthritis (oa) is the most prevalent form of arthritis. its pathogenesis remains poorly understood. though historically regarded as a disease of mechanical degeneration, it is now appreciated that inflammation plays an important role in oa pathogenesis (krasnokutsky et al., 2017). the hallmark of oa is the degradation and loss of articular cartilage, although most tissues of the joint become affected, such as bone, synovium, ligaments, menisci (knee), labrum (hip), periarticular fat, and muscle (englund, 2023).it is believed that there is a pathological link between hyperuricemia and oa therefore, we conducted a cross-sectional study to evaluate an association between elevated sua and radiographic oa of the knee) bipan shrestha, 2019 (.


Eligibility criteria:
inclusion criteria: * adult patient (age\>18 years) with a complaint of knee pain. exclusion criteria: * 1.any patient with a history of trauma to the knee. 2 any patient with knee complaints as a part of autoimmune connective tissue disease.
study of subcutaneous and intravenous velcade in combination with dexamethasone in chinese subjects with relapsed and refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this phase 3 study is to determine if subcutaneous velcade is non-inferior to intravenous velcade when administered in combination with low-dose dexamethasone in chinese refractory or relapsed multiple myeloma (r/rmm) patients. the study will assess the overall response rate after 4 cycles of velcade and dexamethasone administration.


Eligibility criteria:
inclusion criteria: * have received at least 1 and no more than 3 prior lines of therapy for multiple myeloma * have an eastern cooperative oncology group (ecog) performance status score of 0, 1, or 2 * the toxicities resulting from previous therapy must be resolved or stabilized to less than or equal (\<=)grade 1 prior to drug administration * a woman of childbearing potential must have a negative highly sensitive serum (human chorionic gonadotropin \[hcg\]) or urine pregnancy tests at screening within 14 days prior to cycle 1 day 1 * have documented evidence of progressive disease/disease progression based on investigator's determination of response by the international myeloma working group (imwg) criteria on or after their last regimen exclusion criteria: * received antimyeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. the only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day (mg/day) for a maximum of 4 days) before treatment. * received autologous stem cell transplant (asct) within 12 weeks before the date of randomization, or the participant has previously received an allogenic stem cell transplant (regardless of timing) * plans to undergo a stem cell transplant prior to progression of disease on this study, that is, these participants should not be enrolled in order to reduce disease burden prior to transplant * is known to be infected with human immunodeficiency virus (hiv) or active infection with hepatitis b or hepatitis c * had myocardial infarction within 6 months prior to enrollment or has new york heart association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or clinically significant conduction system abnormalities
tearing of membranes before birth - a comparison between two ways of induction of labor pitocin opposite prostaglandin

Conditions: Fetus or Newborn or Maternal; Effects of Induction of Labor

Summary: premature rupture of membranes (prom) is a common occurrence that occurs in the incidence of 8-10% of births. since the duration until delivery is important in avoiding the risk of complications, several studies have been performed in order to understand what is the preferred way to manage this condition of prom in women that are not in active labor. in the largest random study that has been performed 20 years ago, there was found an advantage for labor induction with oxytocin over labor induction with prostaglandin or waiting. however, the most important component - the bishop score, that affects the decision of the labor induction way, was not reported and was not taken into consideration.

premature rupture of membranes (prom) is a common occurrence that occurs in the incidence of 8-10% of births. since the duration until delivery is important in avoiding the risk of complications, several studies have been performed in order to understand what is the preferred way to manage this condition of prom in women that are not in active labor. in the largest random study that has been performed 20 years ago, there was found an advantage for labor induction with oxytocin over labor induction with prostaglandin or waiting. however, the most important component - the bishop score, that affects the decision of the labor induction way, was not reported and was not taken into consideration. therefore, the aim of the study is to compare randomly the perinatal outcomes in women with prom and low bishop between women who undergo labor induction with oxytocin and women who undergo labor induction with prostaglandin e2.

Eligibility criteria:
inclusion criteria: 1. rupture of membranes in bishop score lower than 7. 2. pregnancy week 34+0 and onward. 3. singleton pregnancy. 4. verifying fetal monitoring. 5. normal maternal temperature (lower than 37.8) 6. without vaginal bleeding or suspected placental separation 7. contractions in frequency of less than 3 in 10 minutes 8. signed consent form. exclusion criteria: 1. multiple pregnancy. 2. maternal age below 18 or over 42. 3. active labor 4. contractions in frequency of more than 3 in 10 minutes or cervical dilation ≥2 cm. 5. lack of consent to participate in the study
patch graft material safety and effectiveness in covering glaucoma drainage device tube

Conditions: Primary Open Angle Glaucoma; Primary Angle Closure Glaucoma; Pseudoexfoliation Glaucoma; Pigmentary Glaucoma; Traumatic Glaucoma; Uveitic Glaucoma; Neovascular Glaucoma

Summary: the investigators hypothesize that kerasys is a safe as tutoplast to cover the tube of the molteno 3 glaucoma drainage device during surgery

this study compares patients who will undergo molteno 3 shunt implant surgery with 1 group receiving kerasys patch graft and the 2nd group receiving tutoplast patch graft. the investigators will examine the efficacy and safety of kerasys in comparison with tutoplast and monitor the long term effectiveness for preventing tube erosion in molteno 3 tube shunt surgery for 1 year.

Eligibility criteria:
inclusion criteria: patients with primary open-glaucoma (poag), primary angle-closure glaucoma (pacg), pseudoexfoliation, pigmentary, traumatic, uveitic or neovascular glaucoma exclusion criteria: 1. age ≤ 18 years old. 2. any type of glaucoma other than those listed in the inclusion criteria. 3. less than 3 months of other ocular surgery. 4. active thyroid-related immune orbitopathy, carotid-cavernous fistula, sturge weber syndrome, orbital tumors or orbital congestive disease. 5. patients with connective tissue disorder. 6. patients with congenital or developmental glaucoma. 7. patients with severe dry eye syndrome. 8. patients with any surgical procedure involving revision, removal, or change of the existing glaucoma tube shunt. 9. patients undergoing any surgical concomitant surgical procedure involving the posterior segment. 10. patients with active scleritis, history of ocular trauma including chemical burn, chronic ocular inflammatory disease, or ocular surface disease. 11. patients with any prior history of allergy to the active compound. 12. pregnancy or breast-feeding. 13. patients enrolled in other prospective clinical trials. 14. patients that plan to use contact lens after surgery.
dolastatin 10 in treating patients with recurrent or metastatic soft tissue sarcoma

Conditions: Ovarian Cancer; Sarcoma

Summary: phase ii trial to study the effectiveness of dolastatin 10 in treating patients who have recurrent or metastatic soft tissue sarcoma. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

objectives: i. determine the response rate in patients with recurrent or metastatic soft tissue sarcomas treated with dolastatin 10. ii. determine the toxicity of this regimen in this patient population. outline: this is an open label, multicenter study. patients are stratified according to center, prior therapy, histologic subtype, stage of disease at diagnosis, and current status of disease (recurrent vs metastatic). patients receive dolastatin 10 iv over 10 minutes. treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. patients are followed at 1 month.

Eligibility criteria:
disease characteristics: * histologically proven recurrent or metastatic soft tissue sarcoma * no rhabdomyosarcoma, ewing's sarcoma, chondrosarcoma, osteogenic sarcoma, mesothelioma, or kaposi's sarcoma bidimensionally measurable disease other than previously irradiated disease site(s) even if there has been progression within the radiation field * pulmonary nodule(s) at least 1 x 1 cm no brain metastases patient characteristics: * age: 18 and over * performance status: ecog 0 or 1 * absolute neutrophil count at least 2,000/mm3 * platelet count at least 100,000/mm3 * bilirubin no greater than 1.5 mg/dl * ast and alt less than 1.5 times upper limit of normal (uln) (3 times uln if liver metastases present) * creatinine no greater than 1.5 mg/dl * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 3 months after study * no uncontrolled infection * no history of prior malignancy within the past 5 years except basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other malignancy in complete remission prior concurrent therapy: * no more than 1 prior chemotherapy regimen in the adjuvant setting * no prior chemotherapy for metastatic disease * at least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) * at least 4 weeks since prior radiotherapy * recovered from prior surgery

Keywords: recurrent adult soft tissue sarcoma stage iv uterine sarcoma recurrent uterine sarcoma ovarian sarcoma stage iv adult soft tissue sarcoma
effect of intermittent oro-esophageal tube feeding on severe traumatic brain injury patients with tracheostomy

Conditions: Traumatic Brain Injury

Summary: this was a multicenter randomized controlled study of 98 severe traumatic brain injury patients with tracheostomy. patients enrolled were divided randomly into the observation group with intermittent oro-esophageal tube feeding (n=50) or the control group with nasogastric tube feeding (n=48) for enteral nutrition support, respectively. nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared.

the safe and effective nutrition support for severe traumatic brain injury patients with tracheostomy continues to be a challenge. nasogastric tube feeding has been the mainstream choice in china but with the risk of complications. intermittent oro-esophageal tube feeding is an established modality of enteral nutrition support that can be used with routine treatment. this study reports the clinical outcomes of intermittent oro-esophageal tube feeding vs. nasogastric tube feeding, in patients receiving routine treatment. this was a multicenter randomized controlled study of 98 severe traumatic brain injury patients with tracheostomy. patients enrolled were divided randomly into the observation group with intermittent oro-esophageal tube feeding (n=50) or the control group with nasogastric tube feeding (n=48) for enteral nutrition support, respectively. nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, meeting the diagnosis of severe traumatic brain injury, confirmed through mri * score of glasgow coma scale (gcs) \<8; * presence of no contraindication for enteral nutrition; * with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications; * informed consent form was obtained from the patient\&#39;s family members, indicating their full understanding of the study and agreement to participate. exclusion criteria: * unable to cooperate in completing treatment and assessment due to personal reasons or other disorders; * complicated with other intracranial lesions, such as stroke; * with severe consciousness disorders caused by other diseases.
post-marketing surveillance (special use-results surveillance) on use with liraglutide (victoza®)

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in asia. the aim of this trial is to evaluate safety and effectiveness of victoza® in patients with type 2 diabetes mellitus (t2dm) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * patients with t2dm (type 2 diabetes mellitus) who the physician has decided to start treatment with victoza® in combination with insulin or oad (oral anti-diabetes drug) other than su (sulfonylurea) * male or female, no age limitation exclusion criteria: * previous participation in this study or nn2211-3772 participation is defined as informed consent obtained for this study or enrolment for nn2211-3772 * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * patients who are on victoza® or have previously been on victoza® within 3 month before the enrolment
artificial intelligence-based voice assessment of children and adults respiratory conditions

Conditions: Airway Disease; Cancer of Head and Neck; Radiotherapy; Bronchiolitis; Asthma

Summary: acute and chronic respiratory conditions represent a leading cause of death and morbidity in children and adults worldwide. the diagnosis of bronchiolitis and asthmatic exacerbations is based on clinical, and mostly subjective, clinical parameters with moderately accurate prognostic role. patients undergoing neck radiotherapy need invasive assessments of larynx. a simple biomarker like voice may facilitate the management of these conditions. recent studies showed that voice may be used as a good and easy biomarker to diagnose and monitor several respiratory and non-respiratory conditions. a prospective study aimed to collected voice and other clinical data in adults and children with common acute and chronic respiratory conditions at high impact on healthcare systems will be performed. voice-omic data will be linked with clinical findings generating data integration, using artificial intelligence technology to develop a decision support systems to provide the basis for non-invasive personalised early recognition, diagnosis, monitoring and prognosis of patients with these conditions.


Eligibility criteria:
inclusion criteria: * children with bronchiolitis \<24 months of age clinically characterized according to the clinical definition accepted by international literature (ralstone); * children with asthma according to most recent gina guidance (global initiative for asthma, 2022) aged 6-12 years in a phase of proper control or during acute exacerbations; * adults with upper aerodigestive tract chronic or acute clinical conditions; * adults with pathologic diagnosis of head and neck cancer addressed to radiotherapy with or without chemotherapy for primary treatment of the tumor. exclusion criteria: * children with comorbidities including genetic disorders; * children with other chronic respiratory conditions (bronchodysplasia, cystic fibrosis); * children with primary immunologic diseases; * children with prematurity; * children with other respiratory conditions not part of the inclusion criteria (examples: pneumonia, tonsillitis); * adults over 70 years old or with neurological diseases; * adults with syndromic disease; * adults with malformations of upper aero-digestive tract; * adults with history of head and neck surgery or not able to sustain a vocalism for more than 3 sec.
the significance of sentinel node analysis in colon cancer

Conditions: Colon Cancer

Summary: this study is for the patient with colon cancer, who is going to have colon cancer surgery. the purpose of this research study is to examine a specific lymph node, called the sentinel node. lymph nodes are located throughout your body and cancer may spread by means of those lymph nodes. the sentinel node is the one located closest to your tumor. this study will find out if examining the sentinel node can help to predict disease progression. since the value of this exam is unknown, taking part in this study will not change your clinical care.


Eligibility criteria:
inclusion criteria: * all patients must consent to participate in study * patients will be tracked for five years * a blood test (cea) will be collected every six months * a ct scan will be performed annually * a colonoscopy will be performed at 1 and 5 years post-surgery
ultrasound-guide corrected glenohumeral internal rotation deficit

Conditions: Glenohumeral Internal Rotation Deficit

Summary: background: glenohumeral internal rotation deficit (gird) is believed to be one of the risk factors contributing to shoulder injuries. in addition, athletes with gird of greater than 20° appear to be at a greater risk for the shoulder injuries and surgery. recently, gird can be divided in anatomical gird and pathological gird (pgird). the dominant arm of the athletes with pgird have not only humeral retrotorsion (hr) but also stiffer posterior capsule. the soft-tissue effect is believed to be the key point in pathological cascade of throwers. therefore, the previous studies use gross gird as a risk factor may be modified by ultrasound-guide corrected gird. objective: there are 4 objectives for the present study: (1) to investigate the receiver operating characteristic (roc) curves of the gross gird; (2) to investigate the roc curves of the ultrasound-guide corrected gird; (3) to compare the area under curve (auc) of the two methods; (4) to compare the gross gird and the ultrasound-guide corrected gird in baseball players. design: baseball players who have played baseball for at least 1 year and still active in training or competition will be recruited in this study. participant characteristics will be collected by the main assessor, including age, gender, height, weight, dominant arm, practice time, years of playing baseball. performance/function will be assessed via a kerlan-jobe orthopaedic clinic shoulder and elbow (kjoc) self-report questionnaire. the shoulder rotation rom, ultrasound examination including ultrasound-corrected gird and posterior capsular thickness and posterior shoulder tightness will also be measured. we will follow subjects for a season. once the injury occurs, deterioration or at the end of the season, we will collect the data again. main outcome measures: the shoulder rotation rom, ultrasound examination and posterior shoulder tightness are main outcomes of the study.


Eligibility criteria:
inclusion criteria: 1. age range from 12 to 40 years old. 2. playing baseball for at least 1 year. 3. still active in training or competition. 4. the frequency of training or game should be at least 3 times per week, 3 hours per time. exclusion criteria: 1. subjects with shoulder pain onset due to trauma. 2. a history of shoulder fractures or dislocation. 3. cervical radiculopathy. 4. degenerative joint disease of the shoulder. 5. surgical interventions on the shoulder. 6. inflammatory arthropathy.

Keywords: shoulder injury,ultrasound